DNMT3A and acute myeloid leukemia: Although both types of mutations are predicted to reduce methyltransferase activity, DNMT3AR882 mutations appear to confer a significantly higher risk of progression to acute myeloid leukemia (AML) compared with non-R882 DNMT3A mutations7,8.